MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Key facts

Sponsor

Eli Lilly and Company

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Eli Lilly and Company

Intervention

LY3962673(drug)

Enrollment

630 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2029

Study locations (30)

• City of Hope, Duarte, California, United States
• University of California, Los Angeles (UCLA), Los Angeles, California, United States
• Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
• Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
• Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando, Florida, United States
• Emory University School of Medicine, Atlanta, Georgia, United States
• Community Health Network, Indianapolis, Indiana, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Dana-Farber Cancer Institute, Boston, Massachusetts, United States
• Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
• South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
• New York University (NYU) Langone Medical Center, New York, New York, United States
• David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
• Duke University Medical Center, Durham, North Carolina, United States
• University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for NON RARE IN EUROPE: Non-small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06878274
  Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
  Centre hospitalier de l'Université de Montréal (CHUM)
• RECRUITINGPHASE3NCT07251582
  Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
  Hunan Province Tumor Hospital
• RECRUITINGPHASE2NCT06946797
  A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
  Bristol-Myers Squibb
• RECRUITINGPHASE2NCT07086456
  Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
  Sun Yat-sen University
• RECRUITINGNANCT07086300
  Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
  Kong Fanming
• RECRUITINGPHASE2NCT06620835
  Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
  Groupe Francais De Pneumo-Cancerologie
• RECRUITINGPHASE1, PHASE2NCT06922591
  Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
  Tango Therapeutics, Inc.
• RECRUITINGPHASE3NCT07050043
  Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC
  Dr Arvindran A/L Alaga

See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →